Hypofractionated Stereotactic Radiotherapy for Auditory Canal or Middle Ear Cancer
Hypofractionated Stereotactic Radiotherapy for Auditory Canal or Middle Ear Cancer
复制标题
DOI：
10.1177/107327481602300315
复制
发表时间：
2016-07-01
期刊：
影响因子：
2.6
通讯作者：
Shibamoto, Yuta
中科院分区：
文献类型：
--
作者：
Murai, Taro;Kamata, Shin-Etsu;Shibamoto, Yuta
背景：立体定向放射治疗 (SRT) 可能为患有耳道癌或中耳癌的患者提供一种新的治疗选择。方法：患有病理证实的耳癌的研究参与者接受 SRT（3 次放疗 35 Gy 或 5 次放疗 40 Gy）作为一线治疗。当SRT后局部肿瘤复发时，进行颞骨次全切除和术后放化疗作为挽救治疗。最初的 14 名研究患者接受了推注。结果：29 名研究参与者入组并分期为 T1 (n = 3)、T2 (n = 7)、T3 (n = 14) 或 T4 疾病 (n = 5)。 T1/2 疾病的三年总体生存率为 69%，T3 疾病的三年总体生存率为 79%，T4 疾病的三年总体生存率为 0%。 T1/2疾病的三年局部控制率为70%，T3疾病为50%，T4疾病为20%。在接受推注治疗的研究患者中，2 级或以上皮炎或软组织坏死的发生率更高（8/14 与 2/15；P = .02）。 12 例复发病例安全地进行了挽救治疗。结论：这些结果表明 SRT 对于耳癌患者的结果是有希望的（
Background: Stereotactic radiotherapy (SRT) may represent a new treatment option for individuals with auditory canal or middle ear cancer.Methods: Study participants with pathologically proven ear cancer were treated with SRT (35 Gy for 3 fractions or 40 Gy for 5 fractions) as first-line therapy. When local tumor recurrence developed following SRT, subtotal temporal bone resection and postoperative chemoradiotherapy were performed as salvage treatment. Boluses were used for the initial 14 study patients.Results: Twenty-nine study participants were enrolled and staged with T1 (n = 3), T2 (n = 7), T3 (n = 14), or T4 disease (n = 5). Three-year overall survival rates were 69% for T1/2 disease, 79% for T3 disease, and 0% for T4 disease. Three-year local control rates were 70% for T1/2 disease, 50% for T3 disease, and 20% for T4 disease. Grade 2 or higher dermatitis or soft-tissue necrosis occurred more frequently in study patients treated with boluses (8/14 vs 2/15; P = .02). Salvage treatment was safely performed for 12 recurrent cases.Conclusions: These results suggest that SRT outcomes are promising for patients with ear cancer (